肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 CMRG建议：骨髓瘤表现及其并发症的管理

2021-08-01 加拿大骨髓瘤研究小组 Clin Lymphoma Myeloma Leuk

骨髓瘤

2021年8月，加拿大骨髓瘤研究小组(CMRG)发布骨髓瘤及其并发症的管理建议。

中文标题：

2021 CMRG建议：骨髓瘤表现及其并发症的管理

英文标题：

Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group

发布机构：

加拿大骨髓瘤研究小组

发布日期：

2021-08-01

简要介绍：

2021年8月，加拿大骨髓瘤研究小组(CMRG)发布骨髓瘤及其并发症的管理建议。多发性骨髓瘤（MM）是一种血液系统肿瘤，其症状负担显著。骨病、肾功能不全、细胞减少、感染以及周围神经病变及其他疾病表现和并发症严重影响患者的生活治疗。本文主要针对MM相关临床表现以及并发症的管理提供共识指导。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 CMRG建议：骨髓瘤表现及其并发症的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=728ed1c002211eaa, title=2021 CMRG建议：骨髓瘤表现及其并发症的管理, enTitle=Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group, guiderFrom=Clin Lymphoma Myeloma Leuk, authorId=0, author=, summary=2021年8月，加拿大骨髓瘤研究小组(CMRG)发布骨髓瘤及其并发症的管理建议。, cover=https://img.medsci.cn/20211017/1634479229124_1608702.jpg, journalId=0, articlesId=null, associationId=2018, associationName=加拿大骨髓瘤研究小组, associationIntro=加拿大骨髓瘤研究小组(CMRG,Canadian Myeloma Research Group), copyright=0, guiderPublishedTime=Sun Aug 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年8月，加拿大骨髓瘤研究小组(CMRG)发布骨髓瘤及其并发症的管理建议。多发性骨髓瘤（MM）是一种血液系统肿瘤，其症状负担显著。骨病、肾功能不全、细胞减少、感染以及周围神经病变及其他疾病表现和并发症严重影响患者的生活治疗。本文主要针对MM相关临床表现以及并发症的管理提供共识指导。</span></p>, tagList=[TagDto(tagId=4182, tagName=骨髓瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=10, categoryName=骨科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=4182, guiderKeyword=骨髓瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=6, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4539, appHits=65, showAppHits=0, pcHits=1148, showPcHits=4472, likes=0, shares=5, comments=7, approvalStatus=1, publishedTime=Sun Oct 17 23:05:42 CST 2021, publishedTimeString=2021-08-01, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Sun Oct 17 22:29:42 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Thu Jan 04 17:55:23 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CMRG建议：骨髓瘤表现及其并发症的管理.pdf)])
2021 CMRG建议：骨髓瘤表现及其并发症的管理.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1186388, encodeId=c98f1186388f4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347a6431656, createdName=ms2000001260153689, createdTime=Thu Jan 20 10:51:37 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186387, encodeId=6916118638e7a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347a6431656, createdName=ms2000001260153689, createdTime=Thu Jan 20 10:51:22 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064545, encodeId=2527106454575, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Oct 28 07:01:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062419, encodeId=85d2106241922, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Oct 20 23:47:53 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061753, encodeId=1dc31061e539b, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=4b9a5325687, createdName=宏光医生, createdTime=Tue Oct 19 09:54:24 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2022-01-20 ms2000001260153689

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1186388, encodeId=c98f1186388f4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347a6431656, createdName=ms2000001260153689, createdTime=Thu Jan 20 10:51:37 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186387, encodeId=6916118638e7a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347a6431656, createdName=ms2000001260153689, createdTime=Thu Jan 20 10:51:22 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064545, encodeId=2527106454575, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Oct 28 07:01:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062419, encodeId=85d2106241922, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Oct 20 23:47:53 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061753, encodeId=1dc31061e539b, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=4b9a5325687, createdName=宏光医生, createdTime=Tue Oct 19 09:54:24 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2022-01-20 ms2000001260153689

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1186388, encodeId=c98f1186388f4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347a6431656, createdName=ms2000001260153689, createdTime=Thu Jan 20 10:51:37 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186387, encodeId=6916118638e7a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347a6431656, createdName=ms2000001260153689, createdTime=Thu Jan 20 10:51:22 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064545, encodeId=2527106454575, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Oct 28 07:01:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062419, encodeId=85d2106241922, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Oct 20 23:47:53 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061753, encodeId=1dc31061e539b, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=4b9a5325687, createdName=宏光医生, createdTime=Tue Oct 19 09:54:24 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2021-10-28 微探

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1186388, encodeId=c98f1186388f4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347a6431656, createdName=ms2000001260153689, createdTime=Thu Jan 20 10:51:37 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186387, encodeId=6916118638e7a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347a6431656, createdName=ms2000001260153689, createdTime=Thu Jan 20 10:51:22 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064545, encodeId=2527106454575, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Oct 28 07:01:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062419, encodeId=85d2106241922, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Oct 20 23:47:53 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061753, encodeId=1dc31061e539b, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=4b9a5325687, createdName=宏光医生, createdTime=Tue Oct 19 09:54:24 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2021-10-20 1209e435m98(暂无昵称)

    学习了，谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1186388, encodeId=c98f1186388f4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347a6431656, createdName=ms2000001260153689, createdTime=Thu Jan 20 10:51:37 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186387, encodeId=6916118638e7a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=347a6431656, createdName=ms2000001260153689, createdTime=Thu Jan 20 10:51:22 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064545, encodeId=2527106454575, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Oct 28 07:01:23 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062419, encodeId=85d2106241922, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Oct 20 23:47:53 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061753, encodeId=1dc31061e539b, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=4b9a5325687, createdName=宏光医生, createdTime=Tue Oct 19 09:54:24 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2021-10-19 宏光医生

    学习中

    0

相关指南

接受卡非佐米治疗的骨髓瘤患者心血管不良事件的预防、监测和治疗 欧洲骨髓瘤网络和意大利动脉高血压学会的共识文件 2019

欧洲骨髓瘤网络(EMN,European Myeloma Network) · 2019-07-31

国际骨髓瘤工作组关于单克隆浆细胞疾病成像的共识建议

国际骨髓瘤工作组(IMWG,International Myeloma Working Group) · 2020-01-01

2021 年欧洲骨髓瘤网络关于多发性骨髓瘤的共识声明：如何区分（和管理）Dr. Jekyll and Mr. Hyde

欧洲骨髓瘤网络(EMN,European Myeloma Network) · 2021-07-08

2021 BSH/UKMF指南：骨髓瘤的诊断、调查和初始治疗

英国血液病学学会(BSH,British Society for Haematology) · 2021-03-01

2019 EMN共识：接受卡非佐米治疗的骨髓瘤患者心脏不良事件的预防，检测和治疗

欧洲骨髓瘤网络(EMN,European Myeloma Network) · 2019-02-06

2017 BSH指南：骨髓瘤患者管理中应用影像学检查

英国血液病学学会(BSH,British Society for Haematology) · 2017-07-05

拓展阅读

2014 IMWG共识声明：不能进行自体干细胞移植的骨髓瘤患者的管理，治疗和维持疗法

国际骨髓瘤工作组(IMWG,International Myeloma Working Group) · 2014-01-13

2014 IMWG多发性骨髓瘤的诊断标准（更新版）

国际骨髓瘤工作组(IMWG,International Myeloma Working Group) · 2014-11-01

2015 RACP澳大利亚未获干细胞移植资格的多发性骨髓瘤患者的治疗共识

澳大利亚皇家医师学院(RACP,Royal Australasian College of Physicians) · 2015-03-01

2016 NICE指南：骨髓瘤的诊断和管理（NG.35）

暂未更新 · 2016-02-10

2017 BSH指南：骨髓瘤晚期和长期结果的筛查和管理及其治疗

英国血液病学学会(BSH,British Society for Haematology) · 2017-01-20

2017 ESMO临床实践指南：多发性骨髓瘤的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2017-04-27